SEC Filing Summary: India Globalization Capital, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by India Globalization Capital, Inc. on August 26, 2013. The report discloses the entry into a material definitive agreement on August 22, 2013. Note: The filing identifies the registrant as India Globalization Capital, Inc., not IGC Pharma, Inc.
Key Financial Metrics
This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The document focuses exclusively on the authorization of a potential equity offering.
Material Changes and Agreements
- ATM Agency Agreement: The Company entered into an agreement with Enclave Capital LLC to act as a sales agent.
- Offering Capacity: The Company may offer and sell shares of common stock with aggregate gross proceeds of up to $4 million.
- Sale Method: Sales may be conducted via ordinary brokers' transactions on the NYSE MKT, privately negotiated transactions, or other "at the market" methods defined in Rule 415.
- Pricing Constraints: Shares will be sold at prevailing market prices. No sales will occur below $1.00 per share without Enclave's consent.
- Compensation: Enclave will receive a commission equal to 5% of the gross sales price per share sold.
- Registration: The shares are registered under a shelf registration statement (Form S-3, File No. 333-185502) effective January 4, 2013.
Outlook, Risks, and Management Commentary
Management anticipates that Enclave may provide additional investment banking and financial advisory services for which customary fees may be received. The filing incorporates by reference the "Plan of Distribution" from a prospectus supplement dated August 23, 2013, for further details. No specific risks or contingencies regarding the agreement are detailed in the text of this 8-K beyond standard regulatory disclosures.
Key Facts for Investor Verification
- Verify the current market price of the stock relative to the $1.00 per share floor for sales.
- Confirm the total number of shares authorized for sale under the $4 million cap based on current pricing.
- Review the prospectus supplement dated August 23, 2013, for the full "Plan of Distribution."
- Monitor future filings to determine if and when shares are actually sold under this agreement.
- Clarify the relationship between the registrant name (India Globalization Capital, Inc.) and the user-provided name (IGC Pharma, Inc.).